SPHRY Financials: Starpharma Holdings Limited AI Analysis

Home

Stock

SPHRY

Financials

SPHRY Financial

Starpharma Holdings Limited

$3.25

0.61%

$0.02

At close: Mar 24, 16:00:00 GMT-4

$3.25

Post-market: Mar 24, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$3.23

Open

$3.25

Day's Range

$3.25 - $3.3

52 week range

$0.47 - $3.6

Volume

2.0K

Avg.Volume

1.2K

Dividend yield

EPS (TTM)

-0.05

Market Cap

$136.4M

What is Starpharma Holdings Ltd.?

Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The firm's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The firm's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. The company also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The firm has applied its DEP technology to the innovative area of antibody-drug conjugates.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

SPHRY Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021
Revenue	13	4	9	4	4	2
Revenue Growth (YoY)	333%	-56%	125%	0%	100%	-71%
Cost of Revenue	1	1	0	1	2	0
Gross Profit	12	3	9	3	2	1
Selling, General & Admin	7	6	7	7	6	7
Research & Development	12	12	15	18	18	22
Operating Expenses	16	14	17	18	18	22
Other Non Operating Income (Expenses)	--	--	0	0	0	1
Pretax Income	-3	-9	-8	-15	-16	-19
Income Tax Expense	0	0	0	0	0	0
Net Income	-3	-9	-8	-15	-16	-19
Net Income Growth	-75%	13%	-47%	-6%	-16%	36%
Shares Outstanding (Diluted)	418.89	417.17	411.43	409.03	406.9	396.87
Shares Change (YoY)	1%	1%	1%	1%	3%	7%
EPS (Diluted)	0	-0.02	-0.01	-0.03	-0.03	-0.04
EPS Growth	-75%	21%	-48%	-4%	-20%	26%
Free Cash Flow	-1	-6	-7	-14	-13	-15
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	92.3%	75%	100%	75%	50%	50%
Operating Margin	-23.07%	-250%	-88.88%	-375%	-400%	-1,050%
Profit Margin	-23.07%	-225%	-88.88%	-375%	-400%	-950%
Free Cash Flow Margin	-7.69%	-150%	-77.77%	-350%	-325%	-750%
EBITDA	--	--	--	--	--	--
EBITDA Margin	--	--	--	--	--	--
D&A For EBITDA	--	--	--	--	--	--
EBIT	-3	-10	-8	-15	-16	-21
EBIT Margin	-23.07%	-250%	-88.88%	-375%	-400%	-1,050%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Starpharma Holdings Limited's key financial statements?



According to the latest financial statement (Form-10K), Starpharma Holdings Limited has a total asset of $25, Net loss of $-9

What are the key financial ratios for SPHRY?



Starpharma Holdings Limited's Current ratio is 4.16, has a Net margin is -225, sales per share of $0.

How is Starpharma Holdings Limited's revenue broken down by segment or geography?



Starpharma Holdings Limited largest revenue segment is Dendrimers, at a revenue of 8,289,000 in the most earnings release.For geography, Australia is the primary market for Starpharma Holdings Limited, at a revenue of 8,289,000.

Is Starpharma Holdings Limited profitable?



no, according to the latest financial statements, Starpharma Holdings Limited has a net loss of $-9

Does Starpharma Holdings Limited have any liabilities?



yes, Starpharma Holdings Limited has liability of 6

How many outstanding shares for Starpharma Holdings Limited?



Starpharma Holdings Limited has a total outstanding shares of 418.22

Starpharma Holdings Limited (SPHRY) Financial

SPHRY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Starpharma Holdings Ltd.?

SPHRY Income

Follow-Up Questions

What are Starpharma Holdings Limited's key financial statements?

What are the key financial ratios for SPHRY?

How is Starpharma Holdings Limited's revenue broken down by segment or geography?

Is Starpharma Holdings Limited profitable?

Does Starpharma Holdings Limited have any liabilities?

How many outstanding shares for Starpharma Holdings Limited?